Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- CAR-T Induced Chemobrain in Myeloma
CAR-T Induced Chemobrain in Myeloma
CAR-T induced chemobrain in myeloma is a newly identified and little-understood side effect of CAR-T therapy. What therapies have been developed to manage this side effect?
I identified chemobrain after my autologous stem cell transplant in the early 2000s. The neuropsychologist who helped me identify my cognitive dysfunction thought that damage to a sensitive organ like our brains from toxic regimens would be obvious.
The video below is about chemotherapy-induced chemobrain, meaning the chemobrain that can result from chemotherapy, not specifically from CAR-T therapy. I included it because the video rattles of several treatments that may help.
Tips to treat chemo brain
Whether it’s chemobrain after an ASCT or chemobrain caused by CAR-T therapy, the issue is fixing the problem. I have spent years taking anti-inflammatory supplements, exercising, and eating nutritious foods. Even though I’ve aged, my chemobrain has definitely improved.
As for CAR-T therapy, I would add probiotics to the list of treatments (both before and after) as well as hyperbaric oxygen therapy.
I wish I had learned about the healing properties of HBOT back in the late nineties as this treatment would have helped many of my treatment-induced side effects.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing your MM with both conventional and non-conventional therapies.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy
A recent publication by Geraghty et al. in Cell investigates how chimeric antigen receptor (CAR) T cell therapy can induce cognitive impairment in murine models of both central nervous system (CNS)- and non-CNS-based tumors.1 The authors identified persistent neuroinflammation as a key mechanism underlying these cognitive deficits and successfully explored novel therapeutic strategies, including microglial depletion and CCR3 blockade (Fig. 1).1…
CAR T cell therapy has transformed treatment options for relapsed or refractory hematologic malignancies. Although clinical trials and long-term follow-up studies have confirmed its efficacy and an overall manageable acute toxicity profile, emerging evidence indicates that a subset of patients may develop persistent cognitive deficits post-treatment.2 While most encephalopathic symptoms resolve within the acute stage, typically a few weeks after treatment, a relevant number of patients suffer from long-lasting cognitive deficits such as impairments in memory, word-finding, and attention.2–
In contrast, long-term cognitive side effects remain underrecognized and poorly understood, both in terms of incidence and mechanistic underpinnings. This limited understanding pertains also to therapeutic interventions. Current treatment regimens for CRS and ICANS include the use of corticosteroids and Tocilizumab, an antibody targeting the IL-6 receptor.
However, there are no established interventions for the prevention or treatment of persistent cognitive impairment.2 Over the past years, cancer therapy-related cognitive impairment has gained recognition as a consequence of traditional oncological treatments, including chemotherapy and radiation. These therapies induce sustained neuroinflammation characterized by persistent activation of microglia and astrocytes, leading to reduced differentiation and depletion of oligodendroglial lineage cells.3…
The study further explored the underlying mechanisms of these cognitive impairments and identified persistent neuroinflammation as a key driver…
In light of such emerging evidence, considerations of cognitive side effects of immunotherapy should be included in therapeutic risk-benefit assessments, and additional research should be dedicated to developing strategies to mitigate these long-term consequences.”
CAR-T induced chemobrain in myeloma CAR-T induced chemobrain in myeloma